Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA Partners with University of Bonn, UCB to Study microRNAs in Neurodegeneration

Premium

InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.

According to the company, the alliance is part of the Neuroallianz Consortium, a German-funded academic-industry alliance focused on developing treatments for neurodegenerative conditions.

Specific terms of the partnership were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.